Littleton, CO (August 11th, 2011) – Novus Biologicals, an international supplier of antibodies and antibody-related products to bioscience researchers, has announced a new mouse monoclonal ABCG8 antibody.
ABCG8 is an ATP binding cassette family member which acts to exclude non-cholesterol sterol entry to the intestine, to promote excretion of cholesterol and sterols into bile, and to facilitate transport of sterols back into the intestinal lumen. Novus’ new ABCG8 antibody (Catalog Number NBP1-71706) is useful for highly specific Westerm blot, immunoprecipitation, and immunofluorescence staining on paraffin-embedded mouse samples.
Normal digestion is partially facilitated by the function of ABCG8 and its counterpart ABCG5, which together form a heterodimer which transports cholesterol out of the liver and into bile. Subsequently, cholesterol is eliminated from the bodies of healthy individuals. However, in cases of insulin resistance, this functionality is impaired, and digestion does not result in complete elimination of harmful cholesterol. Unsurprisingly, mutations in ABCG8 can lead to gallstone disease, biliary cancer, hypercholesterolemia and atherosclerosis. In studies related to diabetes, heart disease, and digestive cancers, ABCG8 is commonly assessed for normal expression, function and interaction with ABCG5.
The ABCG8 antibodies are highly characterized and extremely useful tools for cholesterol and lipid metabolism research. We also offer ABCG8 RNAi and various tissue slides and lysates for use as controls.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. The Novus Guarantee + Innovator’s Reward™ Policy 100% guarantees all of Novus’ products to work in the species and applications listed on the datasheet. Novus is a privately held company backed by Mainsail Partners (www.mainsailpartners.com), a San Francisco based private equity firm that invested in Novus in 2008. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
Contact details:
Nehal Saleh, PhD
Novus Biologicals Europe
12 Cambridge Science Park
Cambridge, CB4 0FQ, UK
Tel: +44 (0)1223 426001
Fax: +44 (0)871 971 1635
Email: europe@novusbio.com
Novus Biologicals Worldwide
PO Box 802
Littleton, CO 80160 USA
Tel: 1-888-50-NOVUS
Fax: 303-730-1966
Email: nehal@novusbio.com
